| 邬 麟,蒲兴祥,王倩之.伊立替康联合洛铂或卡铂二线治疗广泛期小细胞肺癌94例临床观察[J].肿瘤学杂志,2013,19(11):872-876. |
| 伊立替康联合洛铂或卡铂二线治疗广泛期小细胞肺癌94例临床观察 |
| Clinical Study of Irinotecan Combined with Lobaplatin or Carboplatin as Second-line Treatment for Ninety-four Cases with Advanced Small Cell Lung Cancer |
| 投稿时间：2013-08-23 |
| DOI：10.11735/j.issn.1671-170X.2013.11.B010 |
|
 |
| 中文关键词: 洛铂 伊立替康 卡铂 小细胞肺癌 药物疗法 |
| 英文关键词:lobaplatin irinotecan carboplatin small cell lung cancer (SCLC) drug therapy |
| 基金项目: |
|
| 摘要点击次数: 2856 |
| 全文下载次数: 1211 |
| 中文摘要: |
| 摘 要：［目的］ 比较伊立替康（CPT-11）联合洛铂(LBP)（IL方案）或联合卡铂（CBP）（IC方案）二线治疗广泛期小细胞肺癌(SCLC)的疗效、不良反应和总生存。［方法］ 94例一线化疗后进展的广泛期SCLC患者，二线治疗随机接受IL方案和IC方案化疗。其中IL方案组48例患者，采用CPT-11 90mg/m2，静滴，d1，8，LBP 30mg/m2，静滴，d1；IC方案组46例患者，CBP AUC=5，静滴d1，CPT-11用药同前。上述方案每21d重复，至少接受1个周期化疗。［结果］ IL方案组和IC方案组患者的总有效率(RR)、疾病控制率(DCR)分别为54.2%(26/48)、32.6%(15/46)和70.8%(34/48)、60.9%(28/46)，IL方案组的RR高于IC方案组 (P=0.040)，两组的DCR无明显差异(P=0.385)；IL和IC方案组的中位无进展生存期(PFS)分别为3.3个月和2.8个月，差异无统计学意义(P=0.127)。IL和IC方案组的总生存期(OS)分别为7.1个月和6.6个月，差异无统计学意义(P=0.203)。两组常见的不良反应为血液学毒性、恶心、呕吐、腹泻及疲乏，IL方案组的血液学毒性谱与IC方案组不同。［结论］ CPT-11联合LBP二线治疗广泛期SCLC近期疗效高于联合CBP，不良反应可耐受，值得进一步研究。 |
| 英文摘要: |
| Abstract：［Purpose］ To compare the efficacy，safety and overall survival of IL regimen consisted of irinotecan (CPT-11) combined with Lobaplatin (LBP) and IC regimen consisted of CPT-11 combined with carboplatin (CBP) as second-line chemotherapy for the patients with extensive small cell lung cancer (SCLC).［Methods］ Ninety-four cases with cases of extensive SCLC who failed in the first-line chemotherapy were randomized received second-line chemotherapy with IL regimen or IC regimen respectively. In the IL regimen group，48 patients were administrated intravenously with CPT-11 90 mg/m2 on d1 and d8，LBP 30mg/m2 on d1，while in IC regimen group，46 patients received CPT-11 at the same dose and CBP AUC=5. Each cycle was repeated every 21 days and the patient must receive at least 1 cycles for evaluation. ［Results］ The response rate(RR) and disease control rate(DCR) in IL regimen group and IC regimen group were 54.2%(26/48)，32.6%(15/46) and 70.8%(34/48)，60.9%(28/46) respectively. The RR in IL regimen group was higher than that in IC regimen group(P=0.040)，and the DCR in two groups did not show significant difference(P=0.385). The progression free survival (PFS) was 3.3 months in IL regimen group and 2.8 months in IC regimen group，with no significant difference(P=0.127). The OS were 7.1 months in IL regimen group and 6.6 months in IC regimen group，with no significant difference(P=0.203). The major toxicities were hematologic toxicities，nausea and vomiting，diarrhea，fatigue and alopecia. There were different spectrum of hematologic toxicities in IL regimen group and IC regimen group. ［Conclusion］ CPT-11 combined with LBP was more effective than CPT-11 combined with CBP for the second-line chemotherapy of the patients with extensive SCLC. It was a well tolerated regimen and worth further study. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |